2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes

San Francisco, CA US
October 7, 2023 to October 8, 2023

The 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes is an oncology conference featuring leading experts in the field of precision oncology who will provide a comprehensive overview of the implications of actionable molecular alterations across common malignancies.

Expert faculty will discuss and analyze the latest scientific findings and practice-changing advances in precision oncology, including the key abstracts relevant to precision oncology presented at the 2023 ASCO Annual Meeting in June 2023.

This conference will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:

  • Integrating different platforms available for testing of actionable molecular alterations for identification of targeted therapy options.
  • Current and evolving paradigms in precision oncology approach for management of common malignancies.
  • Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies.

 

Venue

INTERCONTINENTAL HOTEL SAN FRANCISCO
888 Howard Street
San Francisco, CA 94103

Directions

To receive the discounted rate, please reserve your room by Friday, September 15, 2023, by visiting the link: Hotel Rooms - 2023 Precision Oncology Summit

Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients

Learning Objectives

Upon successful completion of this educational activity on precision oncology, participants will be able to:

  • Identify frequent molecular abnormalities across several common malignancies and understand the appropriate timing of testing to detect these abnormalities.
  • Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
  • Explain the role, including advantages and disadvantages, of different testing methodologies available for a selection of targeted therapies.
  • Plan optimal molecular-targeted treatment strategies for the treatment of cancer.
  • Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in a clinical investigation for cancer patients.

 

Bronze Sponsor: 

Course summary
Available credit: 
  • 13.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 13.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 13.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 13.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 13.25 Contact Hours.
Course opens: 
03/10/2023
Course expires: 
01/08/2024
Event starts: 
10/07/2023 - 3:00pm PDT
Event ends: 
10/08/2023 - 4:30pm PDT
Cost:
$350.00
Add to calendar: 

Read the live coverage of this meeting - https://thecancernews.org/2023-precision-oncology-summit/

 

Conference Chair: Dr. Alan Ashworth

Conference Co-Chairs: Dr. Mark Pegram and Dr. Pamela Munster

Associate Chair: Dr. Siddhartha Yadav

DAY 1- October 7th, 2023

All times below are listed in Pacific Standard Time (PST)

07:00 AM – 08:00 AM – REGISTRATION & EXHIBITS

08:00 AM – 08:05 AM – Welcome and Introduction – Alan Ashworth, PhD, FRS

08:05 AM – 08:15 AM –  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD 

08:15 AM – 09:00 AM – Session 1: Precision Oncology

Session Chair: Xiuning Le, MD, PhD

08:15 AM – 08:30 AM – Precision Oncology 101 - Christina Lockwood, PhD, DABCC, FAACC, DABMGG

08:30 AM – 08:45 AM – Molecular Pathogenesis in Cancer – Identification of Drivers and Therapeutic Targets - Rachel Schiff, PhD

08:45 AM – 09:00 AM – Panel Discussion/Q & A

09:00 AM – 010:00 AM –  Session 2: The Revolution in Germline DNA Testing

Session Chair: Marianne Dubard-Gault, MD, MS

09:00 AM – 09:20 AM – Controversies in Germline Genetic Testing - Pamela Munster, MD

09:20 AM – 09:40 AM – Diagnostic and Therapeutic Opportunities From Germline DNA Sequence Analysis - Siddhartha Yadav, MBBS, MD

09:40 AM – 10:00 AM – Panel Discussion/Q & A

10:00 AM – 10:15 AM – BREAK & EXHIBITS  

10:15 AM – 11:15 AM – Session 3: Cell Therapy 

Session Chair: Krishna Komanduri, MD

10:15 AM – 10:25 AM – Cell Therapy Overview- Recent Advances and Future Directions - Krishna Komanduri, MD

10:25 AM – 10:35 AM –  Novel Signaling Strategies for CAR-T Therapies in Solid Tumors - Greg Allen, MD, PhD

10:35 AM – 10:45 AM – Improving the Success of CAR T-Cells and Applications to Solid Tumors - Julia Carnevale, MD

10:45 AM – 10:55 AM – CAR-T Therapy for Hematologic Malignancies: Recent Advances and Future Directions - Michael A. Spinner, MD

10:55 AM – 11:15 AM – Cased-Based Panel Discussion With Audience Q & A 

11:15 AM – 11:55 AM – KEYNOTE- PARP Inhibitors as a New Cancer Therapy Paradigm: History, Challenges and Opportunities - Alan Ashworth, PhD, FRS

11:55 AM – 12:55 PM – LUNCH BREAK & EXHIBITS

Product Theater Sponsored by Merck *Non CME Activity* in Marina Room

Title: A Treatment Option for Certain Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Speaker: David J. Benjamin, MD

12:55 PM – 02:10 PM – Session 4: Precision Medicine in Hematologic Malignancies 

Session Chair: Shaji Kumar, MD

12:55 PM – 01:10 PM – Targeting the Genetic Aberrations in Myeloid Neoplasms - Karilyn Larkin, MD

01:10 PM – 01:25 PM – Novel Therapies in ALL – Individualizing Therapy - Matthew Joseph Wieduwilt, MD

01:25 PM – 01:40 PM – Individualized Therapy in Myeloma - Shaji Kumar, MD

01:40 PM – 01:55 PM – Precision Medicine in Lymphomas – Where Are We? - Grzegorz (Greg) S. Nowakowski, M.D., FASCO

01:55 PM – 02:10 PM – Panel Discussion/Q & A

2:10 PM– 3:10 PM–  Session 5: Precision Oncology in Gastrointestinal Malignancies 

Session Chair: George A. Fisher Jr. MD, PhD

02:10 PM – 02:25 PM – Basic Science in Gastrointestinal Precision Oncology - Hanlee Ji, MD

02:25 PM – 02:40 PM – Translational Science Considerations in Gastrointestinal Malignancies - Chris Chen, MD

02:40 PM – 02:55 PM – Clinical Considerations of Precision Oncology in Gastrointestinal Malignancies - Eric Collisson, MD

02:55 PM – 03:10 PM – Panel Discussion/Q & A

03:10 PM – 03:25 PM – BREAK & EXHIBITS

03:25 PM – 04:10 PM – Molecular Tumor Board I – Case-Based Presentations

Session Chair: Howard L. McLeod, PharmD

Case-Based Presentations: Siddhartha Yadav, MBBS, Chandrikha Chandrasekharan, MBBS, Mark Pegram, MD, Charity Huang, MD

04:10 PM – 05:10 PM – Oral Abstract Presentations

Session Chairs: Jonathan Wesley Riess, MD, MS, Umang Swami, MD, MS

04:10 PM – 04:22 PM – Developing Cell Surface Target Discovery Pipeline in Metastatic Thymic Epithelial Tumors (mTET) - Fatemeh Ardeshir Larijani, MD

04:22 PM – 04:34 PM – Tumor Transcriptomic Profiling of Patients (pts) With Metastatic Castration Sensitive Prostate Cancer (mCSPC) Who Do Not Achieve Optimal PSA Response to Intensified Androgen Deprivation Therapy (ADT-I) - Vinay Mathew Thomas, MBBS

04:34 PM – 04:46 PM –  Population Health and Cancer Testing (PHACT) Study: A Model for Providing Cancer Gene Panel Testing in a Community-Recruited Multi-Ethnic Population - Leticia Taniwaki, MD

04:46 PM – 04:58 PM – Differences in Tumor Transcriptomic Profile of Advanced Prostate Cancer (PCa) Patients (pts) With and Without Diabetes Mellitus (DM) - Gliceida Galarza Fortuna, MD

04:58 PM – 05:10 PM – Immunotherapy in Advanced NSCLC by ARID1A Mutational Status: A Case-Control Analysis by ctDNA - Ebaa Al- Obeidi, MD

5:10 PM – Poster Viewing and Reception


DAY 2- October 8th, 2023

07:00 AM – 08:00AM – REGISTRATION & EXHIBITS

08:00 AM – 09:00 AM – Session 6: Precision Medicine Clinical Science Symposium: Breast Cancer 

Session Chair: Mark Pegram, MD

08:00 AM – 08:15 AM – Update of Basic Science Developments in Precision Oncology for Breast Cancer - Joshua Gruber, MD, PhD

08:15 AM – 08:30 AM – Translational Considerations in Precision Oncology in Breast Cancer - Christina Curtis, PhD, MSc

08:30 AM – 08:45 AM – Clinical Developments in Precision Oncology for Breast Cancer - Hope Rugo, MD, FASCO

08:45 AM – 09:00 AM – Panel Discussion/Q & A

09:00 AM – 10:00 AM – Session 7: Precision Medicine Clinical Science Symposium: Lung Cancer 

Session Chair: Jonathan Wesley Riess, MD, MS

09:00 AM – 09:15 AM – Basic Science/Molecular Pathogenesis of Lung Cancer - Alex A. Adjei, MD, PhD, FACP

09:15 AM – 09:30 AM – Translational Science Update of Precision Oncology Methods in Lung Cancer - Joel W Neal, MD. PhD

09:30 AM – 09:45 AM – Clinical Application of Precision Oncology in Lung Cancer - Millie Das, MD

09:45 AM – 10:00 AM – Panel Discussion/Q & A

10:00 AM – 10:15 AM – BREAK & EXHIBITS

10:15 AM – 11:15 AM – Session 8: Precision Medicine in Genitourinary Oncology

Session Chair: Alice Fan, MD

10:15 AM – 10:30 AM – Basic Science of Precision Oncology in Genitourinary Oncology - Russell K Pachynski, MD

10:30 AM – 10:45 AM – Translational Science in Genitourinary Precision Oncology - Arlene O Siefker-Radtke, MD

10:45 AM – 11:00 AM – Clinical Considerations of Precision Oncology in Genitourinary Malignancies - Ulka Vaishampayan, MD

11:00 AM – 11:15 AM- Panel Discussion/ Q & A

11:15 AM – 12:15 PM – Session 9: Precision Oncology in Solid Tumor Malignancies

Session Chair: Michael Wagner, MD

11:15 AM – 11:30 AM – Tissue-Agnostic Drug Development in Precision Oncology - Peter J. O'Dwyer, MD

11:30 AM – 11:45 AM – Precision Medicine in Sarcoma Management 

11:45 AM – 12:00 PM – Precision Medicine in Dermatologic Malignancies - Pauline Funchain, MD

12:00 PM – 12:15 PM – Panel Discussion/ Q & A

12:15 PM – 01:15 PM – LUNCH & EXHIBITS 

01:15 PM – 02:15 PM – Molecular Tumor Board II – Case-Based Presentations 

Session Chair: Jason Brown, MD, PhD

Case-Based Presentations: Michelle Melisko, MD, Marianne Dubard-Gault, MD, MS, Jason Brown, MD, PhD

02:15 PM – 03:00 PM – Session 10: Implementation of Precision Oncology into the Diagnostic and Therapeutic Armamentarium

Session Chair: Raid Aljumaily, MD

02:15 PM – 02:30 PM – Molecular Imaging in Precision Oncology - Andrei Iagaru, MD

02:30 PM – 02:45 PM – Machine-Learning (ML)  in Precision Oncology – Predicting Target Structure - Manish Kohli, MD

02:45 PM – 03:00 PM – Panel Discussion/ Q & A

03:00 PM – Chairperson’s Concluding Remarks

INTERCONTINENTAL HOTEL SAN FRANCISCO
888 Howard Street
San Francisco, CA 94103
United States
+1 (415) 616-6627

A limited number of rooms have been reserved at the InterContinental Hotel San Francisco for attendees and exhibitors of the 2023 Precision Oncology Summit at a discounted rate of $329/night. Hotel check-in time is 4:00 pm on the day of arrival and check-out time is 11:00 am on the day of departure. For a smooth and successful stay, please advise the hotel staff of your estimated time of arrival and departure, daily itineraries, and any other pertinent information. 

Please reserve your room by the cut-off date, Friday, September 15, 2023, by visiting the link below:

Hotel Rooms - 2023 Precision Oncology Summit

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Alan Ashworth, PhD, FRS

has a financial relationship (Stock) with Ovibio;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Stock Options) with Ambagon;.
has a financial relationship (Stock Options) with Hap10;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Stock) with Azkarra Therapeutics;.
has a financial relationship (Stock) with Cambridge Science Corporation;.
has a financial relationship (Stock Options) with Bluestar;.
has a financial relationship (Stock Options) with Yingli;.
has a financial relationship (Stock Options) with ProLynx;.
has a financial relationship (Stock) with Tango Therapeutics;.
has a financial relationship (Stock Options) with Cytomx;.
has a financial relationship (Stock) with Gladiator;.
has a financial relationship (Stock Options) with Phoenix Molecular Designs;.
has a financial relationship (Stock Options) with Oric;.
has a financial relationship (Patent) with AstraZeneca;.
has a financial relationship (Stock) with Kyttaro;.
has a financial relationship (Independent contractor) with Circle;.
has a financial relationship (Stock Options) with Earli;.
has a financial relationship (Stock Options) with Trial Library;.
has a financial relationship (Independent contractor) with GSK;.

Pamela Munster

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Revolution;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Clovis;.
has a financial relationship (Grant Or Contract) with genetech;.
has a financial relationship (Independent contractor) with Johnson and Johnson ;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Seagen;.

Mark Pegram, MD

has a financial relationship (Other) with Novartis;.
has a financial relationship (Employment) with Rain Oncology;.
has a financial relationship (Other) with Gilead;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

ALEX ADJEI, ALEX A. ADJEI, MD:PhD

has no relevant financial relationships to disclose at this time.

Ebaa Al-Obeidi, MD

has no relevant financial relationships to disclose at this time.

Raid Aljumaily, MD

has no relevant financial relationships to disclose at this time.

Greg Allen

has no relevant financial relationships to disclose at this time.

Fatemeh Ardeshir Larijani

has no relevant financial relationships to disclose at this time.

Alan Ashworth, PhD, FRS

has a financial relationship (Stock) with Cambridge Science Corporation;.
has a financial relationship (Stock Options) with Bluestar;.
has a financial relationship (Stock Options) with Yingli;.
has a financial relationship (Stock Options) with ProLynx;.
has a financial relationship (Stock) with Azkarra Therapeutics;.
has a financial relationship (Stock Options) with Cytomx;.
has a financial relationship (Stock) with Gladiator;.
has a financial relationship (Stock Options) with Phoenix Molecular Designs;.
has a financial relationship (Stock Options) with Oric;.
has a financial relationship (Patent) with AstraZeneca;.
has a financial relationship (Stock) with Tango Therapeutics;.
has a financial relationship (Stock) with Kyttaro;.
has a financial relationship (Independent contractor) with Circle;.
has a financial relationship (Stock Options) with Earli;.
has a financial relationship (Stock Options) with Trial Library;.
has a financial relationship (Independent contractor) with GSK;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Stock Options) with Ambagon;.
has a financial relationship (Stock Options) with Hap10;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Stock) with Ovibio;.

Jason Brown

has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with EMD Serono;.

Julia Carnevale, MD

has no relevant financial relationships to disclose at this time.

Chandrikha Chandrasekharan, MBBS

has no relevant financial relationships to disclose at this time.

Christopher Chen

has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Professional Services) with Boxer Capital;.
has a financial relationship (Grant Or Contract) with Oric Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Merus;.
has a financial relationship (Professional Services) with Guidepoint Global Advisors;.
has a financial relationship (Grant Or Contract) with Kinnate Biopharma;.
has a financial relationship (Grant Or Contract) with Rain Oncology;.
has a financial relationship (Grant Or Contract) with Gilead Sciences;.
has a financial relationship (Grant Or Contract) with ADC Therapeutics;.
has a financial relationship (Grant Or Contract) with Mersana Therapeutics;.

Eric Collisson, Professor of Medicine

has no relevant financial relationships to disclose at this time.

Christina Curtis, PhD, MSc

has a financial relationship (Stock) with Grail/Illumina;.
has a financial relationship (Stock) with DeepCell;.
has a financial relationship (Other) with NanoString;.
has a financial relationship (Independent contractor) with Bristol Myers Squibb;.
has a financial relationship (Other) with ResistanceBio;.
has a financial relationship (Independent contractor) with 3T Biosciences;.
has a financial relationship (Stock) with RAVEL Biotechnology;.
has a financial relationship (Independent contractor) with Genentech;.

Millie Das, MD

has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with Sanofi/Genzyme;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with CellSight;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Professional Services) with Eurofins;.
has a financial relationship (Grant Or Contract) with Genentech;.

george fisher, MD PhD

has a financial relationship (Professional Services) with genentech/roche;.
has a financial relationship (Professional Services) with hutchison pharma;.
has a financial relationship (Stock) with seattle genetics;.
has a financial relationship (Professional Services) with astra zeneca;.
has a financial relationship (Professional Services) with merck;.

Pauline Funchain, MD

has a financial relationship (Other) with Nirvana Healthcare Ventures;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with GigaGen;.
has a financial relationship (Grant Or Contract) with Taiho Oncology;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Independent contractor) with BMS;.

Gliceida Galarza Fortuna

has no relevant financial relationships to disclose at this time.

Joshua Gruber, MD, PhD

has a financial relationship (Independent contractor) with Guidepoint;.
has a financial relationship (Grant Or Contract) with Hummingbird Bioscience;.
has a financial relationship (Employment) with Guardant Health;.
has a financial relationship (Independent contractor) with Sharma Therapeutics;.

Charity Huang, MD

has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Theradex Oncology;.
has a financial relationship (Other) with Natera;.
has a financial relationship (Other) with Regeneron;.
has a financial relationship (Other) with Seagen;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Eli Lilly;.
has a financial relationship (Other) with Roche/Genentech;.

Andrei Iagaru, MD

has a financial relationship (Grant Or Contract) with RayzeBio;.
has a financial relationship (Grant Or Contract) with Lantheus;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Other) with Clarity Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with GE Healthcare;.
has a financial relationship (Other) with Alpha9Tx;.
has a financial relationship (Other) with Radionetics;.
has a financial relationship (Grant Or Contract) with Telix;.

Hanlee Ji, MD

has a financial relationship (Grant Or Contract) with 10X Genomics;.
has a financial relationship (Travel) with Oxford Nanopore;.

Manish Kohli

has a financial relationship (Independent contractor) with Genapsys Inc.;.
has a financial relationship (Independent contractor) with Bristol Meyer Squibb/Celgene;.

Krishna Komanduri, MD

has a financial relationship (Independent contractor) with Avacta Therapeutics;.
has a financial relationship (Independent contractor) with CRISPR Therapeutics;.
has a financial relationship (Independent contractor) with Roche;.
has a financial relationship (Independent contractor) with Optum Health;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Iovance;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Cargo Therapeutics;.

Karilyn Larkin

has a financial relationship (Other) with Astellas;.

Christina Lockwood, PhD

has a financial relationship (Professional Services) with LGC Group;.

Vinay Mathew Thomas

has no relevant financial relationships to disclose at this time.

Howard McLeod

has no relevant financial relationships to disclose at this time.

Michelle Melisko

has a financial relationship (Other) with Astra Zeneca;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Grant Or Contract) with Daewha;.
has a financial relationship (Stock) with Merrimack;.
has a financial relationship (Other) with Daichi Sankyo;.
has a financial relationship (Grant Or Contract) with OBI Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Novartis;.

Pamela Munster

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Revolution;.
has a financial relationship (Grant Or Contract) with Clovis;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with genetech;.
has a financial relationship (Independent contractor) with Johnson and Johnson ;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Seagen;.

Joel Neal, MD, PhD

has a financial relationship (Other) with GSK;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Eli Lilly and Company;.
has a financial relationship (Other) with Regeneron Pharmaceuticals;.
has a financial relationship (Other) with Surface Oncology;.
has a financial relationship (Other) with AbbVie;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Other) with Takeda Pharmaceuticals;.
has a financial relationship (Other) with Blueprint Pharmaceuticals;.
has a financial relationship (Other) with D2G Oncology;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Novocure;.
has a financial relationship (Other) with Adaptimmune;.
has a financial relationship (Other) with CME Matters, Clinical Care Options CME, Research to Practice CME, Medscape CME, Biomedical Learning Institute CME, MLI Peerview CME, Prime Oncology CME, Projects in Knowledge CME, Rockpointe CME, MJH Life Sciences CME, Medical Educator Consortium, HMP Edu;.
has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Iovance Biotherapeutics;.
has a financial relationship (Other) with Sanofi/Regeneron;.
has a financial relationship (Other) with Mirati Therapeutics;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Nektar Therapeutics;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with Genentech/Roche;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Natera;.
has a financial relationship (Other) with Turning Point Therapeutics;.
has a financial relationship (Other) with Summit Therapeutics;.
has a financial relationship (Other) with Boehringer Ingelheim;.

Grzegorz Nowakowski, MD

has a financial relationship (Professional Services) with Bristol-Myers Squibb;.
has a financial relationship (Professional Services) with Daiichi Sankyo, Inc.;.
has a financial relationship (Professional Services) with Bantam Pharmaceutical, LLC;.
has a financial relationship (Professional Services) with Blueprint Medicines Corporation;.
has a financial relationship (Professional Services) with TG Therapeutics, Inc;.
has a financial relationship (Professional Services) with Selvita Inc;.
has a financial relationship (Professional Services) with MorphoSys AG;.
has a financial relationship (Professional Services) with Seagen;.
has a financial relationship (Professional Services) with Karyopharm Therapeutics;.
has a financial relationship (Professional Services) with TG Therapeutics, Inc;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Incyte Corporation;.
has a financial relationship (Professional Services) with Celgene Corporation;.
has a financial relationship (Professional Services) with Curis;.
has a financial relationship (Professional Services) with Constellation Pharmaceuticals;.
has a financial relationship (Professional Services) with Kite Pharma, Inc.;.
has a financial relationship (Professional Services) with Kymera Therapeutics;.
has a financial relationship (Professional Services) with AbbVie Inc.;.
has a financial relationship (Professional Services) with MEI Pharma;.
has a financial relationship (Professional Services) with Ryvu Therapeutics;.
has a financial relationship (Professional Services) with F Hoffmann-La Roche Limited;.
has a financial relationship (Professional Services) with Karyopharm Therapeutics;.
has a financial relationship (Professional Services) with Zai Laboratory;.
has a financial relationship (Professional Services) with Constellation Pharmaceuticals;.
has a financial relationship (Professional Services) with Fate Therapeutics ;.
has a financial relationship (Professional Services) with Debiopharm;.
has a financial relationship (Professional Services) with Genentech Inc;.

Peter O'Dwyer

has a financial relationship (Grant Or Contract) with Five Prime;.
has a financial relationship (Grant Or Contract) with BBI;.
has a financial relationship (Grant Or Contract) with Lilly/Imclone;.
has a financial relationship (Grant Or Contract) with Minneamrata;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Syndax;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Taiho;.
has a financial relationship (Grant Or Contract) with Mirati ;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Celgene;.
has a financial relationship (Grant Or Contract) with h3biomedicine;.
has a financial relationship (Grant Or Contract) with abbvie;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with FortySeven;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with array;.
has a financial relationship (Grant Or Contract) with pharmacyclics;.

Russell Pachynski, MD

has a financial relationship (Other) with Dendreon;.
has a financial relationship (Other) with Blue Earth;.
has a financial relationship (Grant Or Contract) with Pharmacyclics;.
has a financial relationship (Other) with Bayer;.
has a financial relationship (Grant Or Contract) with Genetech/Roche;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Merck ;.

Hope Rugo

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Daiichi;.
has a financial relationship (Grant Or Contract) with Boehringer Ingelheim;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Roche ;.
has a financial relationship (Grant Or Contract) with Sermonix;.
has a financial relationship (Grant Or Contract) with Ayala;.
has a financial relationship (Professional Services) with NAPO;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Grant Or Contract) with Macrogenics;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Professional Services) with Samsung;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Polyphor;.
has a financial relationship (Professional Services) with Puma;.

Rachel Schiff

has a financial relationship (Grant Or Contract) with Puma biotechnology;.
has a financial relationship (Independent contractor) with Macrogenics;.
has a financial relationship (Independent contractor) with Daiichi Sankyo;.

Arlene Siefker-Radtke, MD

has a financial relationship (Grant Or Contract) with Millennium;.
has a financial relationship (Professional Services) with Bristol Myers Squibb;.
has a financial relationship (Professional Services) with Ideeya Biosciences ;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Grant Or Contract) with Basilea Pharmaceutica;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with Bavarian Nordic;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Taiho;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with G1 Therapeutics;.
has a financial relationship (Professional Services) with Loxo;.
has a financial relationship (Professional Services) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Nektar Therapeutics;.

Michael Spinner, MD

has a financial relationship (Independent contractor) with Kite Pharma;.

Leticia Taniwaki, MD

has no relevant financial relationships to disclose at this time.

Ulka Vaishampayan, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with sanofi;.

Michael Wagner, M.D.

has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Deciphera;.
has a financial relationship (Independent contractor) with Adaptimmune;.
has a financial relationship (Independent contractor) with Aadi;.

Matthew Wieduwilt

has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Advisory Board;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Sorrento ;.
has a financial relationship (Professional Services) with Jazz;.
has a financial relationship (Professional Services) with BMS;.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has no relevant financial relationships to disclose at this time.
Moderator(s)

Marianne Dubard-Gault, MD, MS

has no relevant financial relationships to disclose at this time.

Alice Fan, MD

has a financial relationship (Stock) with Molecular Decisions;.

Shaji Kumar, MD

has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.
has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.

Xiuning Le, MD PhD

has a financial relationship (Stock Options) with Bloomhills;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Blueprint;.
has a financial relationship (Independent contractor) with Pinetree;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with EMD Serono;.
has a financial relationship (Independent contractor) with Abion;.
has a financial relationship (Independent contractor) with Teligene;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Daiichi;.
has a financial relationship (Independent contractor) with SystImmune;.

Mark Pegram, MD

has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Employment) with Rain Oncology;.

Jonathan Riess, MD, MS

has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Beigene;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Professional Services) with Jazz Pharmaceuticals;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with EMD Serano;.
has a financial relationship (Professional Services) with Turning Point;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Biodesix;.
has a financial relationship (Professional Services) with Bayer;.
Planning committee(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Available Credit

  • 13.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 13.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 13.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 13.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 13.25 Contact Hours.

Price

Cost:
$350.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $350

Non-physician HCP (non-industry) - $250

Industry representatives - $1250

Fellow or resident - $200

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

Cancellation Policy

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.